Formoterol ( DrugBank: Formoterol )

---

3 diseases

ID	Disease name (Link within this page)	Number of trials
85	Idiopathic interstitial pneumonia	1
228	Bronchiolitis obliterans	2
299	Cystic fibrosis	1

85. Idiopathic interstitial pneumonia

---

Clinical trials : 598 /  Drugs : 435 - (DrugBank : 116) / Drug target genes : 100 - Drug target pathways : 210

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2013-004404-19-GB (EUCTR)	07/05/2014	25/03/2014	Effect of Fostair® on biomarkers of platelet adhesion in Idiopathic pulmonary fibrosis	A Randomized, Double-blind, Placebo-controlled, Crossover Study toAssess the Effect of 28 Day Treatment with Fostair® pMDI 200/12 on biomarkers of platelet adhesion in Patients with Idiopathic pulmonary fibrosis. - Effect of Fostair® pMDI on biomarkers of platelet adhesion in IPF	Idiopathic pulmonary fibrosis MedDRA version: 16.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	Trade Name: Fostair INN or Proposed INN: beclometasone dipropionate INN or Proposed INN: formoterol fumarate dihydrate	Hull and East Yorkshire Hospitals NHS Trust	NULL	Not Recruiting			Female: yes Male: yes			United Kingdom

228. Bronchiolitis obliterans

---

Clinical trials : 96 /  Drugs : 125 - (DrugBank : 34) / Drug target genes : 33 - Drug target pathways : 155

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01560689 (ClinicalTrials.gov)	June 2008	20/3/2012	Inhaled BUDESONIDE/FORMOTEROL in Bronchiolitis Obliterans Following Stem Cell Transplantation	Open-labeled Trial to Evaluate the Therapeutic Effects of Inhaled BUDESONIDE/FORMOTEROL in Bronchiolitis Obliterans After Allogeneic Stem Cell Transplantation	Bronchiolitis Obliterans;Allogeneic Stem Cell Transplantation	Drug: Budesonide/formoterol;Drug: Placebo	Assistance Publique - Hôpitaux de Paris	NULL	Completed	16 Years	N/A	Both	32	Phase 2	France
2	NCT00624754 (ClinicalTrials.gov)	March 2008	15/2/2008	Prospective Evaluation of the Efficacy of Budesonide/Formoterol in Bronchiolitis Obliterans in AHSCT	recipientsProspective Evaluation of the Efficacy of Budesonide/Formoterol (Symbicort®) in Bronchiolitis Obliterans in Allogeneic Haematopoietic Stem Cell Transplantation (AHSCT) Recipients	Obstructive Airway Disease	Drug: Formoterol/Budesonide;Drug: lactose	Assistance Publique - Hôpitaux de Paris	AstraZeneca	Completed	16 Years	N/A	Both	32	Phase 2	France

299. Cystic fibrosis

---

Clinical trials : 1,696 /  Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00728715 (ClinicalTrials.gov)	January 2004	31/7/2008	Efficacy of Budesonide-Formoterol in Bronchiectasis	Clinical Efficacy and Safety of Budesonide and Formoterol in the Management of Non-Cystic Fibrosis Bronchiectasis	Bronchiectasis	Drug: budesonide-formoterol single inhaler;Drug: High dose of budesonide;Drug: A;Drug: B	Hospital General de Requena	Esteve Labs (Grant)	Completed	18 Years	80 Years	Both	40	N/A	Spain